Sep 22, 2021 Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer Learn More
Sep 15, 2021 Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Learn More
Aug 18, 2021 Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia Learn More
Aug 16, 2021 Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Learn More